<DOC>
	<DOCNO>NCT01094184</DOCNO>
	<brief_summary>This open-label , multi-centre study evaluate safety , tolerability effect disease progression , survival time Karnofsky performance status bevacizumab ( Avastin ) combination taxane monotherapy female patient oestrogen- , progesterone- HER2-receptor negative ( triple-negative ) breast cancer . Patients eligible participate study receive prior chemotherapy metastatic breast cancer investigator 's opinion , require combination therapy treatment disease . Patients receive taxane ( weekly paclitaxel three-weekly docetaxel ) bevacizumab ( 10 mg/kg every 2 week 15 mg/kg every 3 week intravenously infusion ) . The treatment continue disease progression . The target sample size &lt; 100 patient .</brief_summary>
	<brief_title>A Study Avastin With Taxane Therapy Patients With Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Adult patient &gt; /=18 year age Histologically confirm triplenegative ( oestrogen progesterone receptor ( ER/PgR ) HER2 receptor negative ) adenocarcinoma breast metastatic disease Patient Investigator 's opinion require combination therapy disease Life expectancy &gt; /=12 week Previous chemotherapy metastatic breast cancer ( adjuvant chemotherapy allow ) Patients currently undergo radiation therapy treatment metastatic disease ( apart relief metastatic bone pain ) Major surgery significant traumatic injury within 28 day prior enrollment anticipation need major surgery study treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>